Literature DB >> 18469329

Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE).

Michael Bonelli1, Anastasia Savitskaya, Karolina von Dalwigk, Carl Walter Steiner, Daniel Aletaha, Josef S Smolen, Clemens Scheinecker.   

Abstract

The objective of the study was that the regulatory T cells (Treg) that specialize in the suppression of immune responses might be critically involved in the pathogenesis of autoimmune disease. As for systemic lupus erythematosus (SLE), however, published data concerning Treg phenotype and function are partly conflicting. We therefore performed quantitative and qualitative analyses of naturally occurring CD4(+)CD25(+) Treg from SLE patients as compared with healthy controls (HC) in order to further elucidate the role of Treg in this systemic autoimmune disease. The phenotype of peripheral blood CD4(+)CD25(+) Treg was determined by flow cytometry (FACS) in SLE patients and HC. Treg were isolated from SLE patients and HC and their functional capacity was analyzed in suppression assays. Phenotypic and functional data were correlated with clinical data. Decreased proportions of CD4(+) Treg with high-level expression of CD25 (CD4(+)CD25(hi)) were observed in active and inactive SLE patients (0.96 +/- 0.08 and 1.17 +/- 0.08%, respectively) as compared with HC (2 +/- 0.1%). In contrast to HC, Treg from SLE patients displayed an activated phenotype as determined by the expression of CD69, CD71 and HLA-DR. The suppressive capacity of isolated Treg from SLE patients, however, was significantly reduced as compared with HC. Proportions of CD4(+)CD25(hi) T cells and the suppressive capacity of Treg were inversely correlated with the clinical disease activity in SLE patients. Our data describe quantitative and qualitative defects of Treg in SLE patients. These deficiencies might contribute to the breakdown of self-tolerance and the development of the autoimmune response in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469329     DOI: 10.1093/intimm/dxn044

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  75 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 3.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

4.  Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study.

Authors:  J Baraut; E I Grigore; F Jean-Louis; S H Khelifa; C Durand; F Verrecchia; D Farge; L Michel
Journal:  Bone Marrow Transplant       Date:  2013-12-23       Impact factor: 5.483

5.  Frequently Increased but Functionally Impaired CD4+CD25+ Regulatory T Cells in Patients with Oral Lichen Planus.

Authors:  Leilei Zhou; Tianyi Cao; Yufeng Wang; Hui Yao; Guanhuan Du; Guangjie Chen; Xiaoyin Niu; Guoyao Tang
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

6.  Levels of regulatory T cells CD69(+)NKG2D(+)IL-10(+) are increased in patients with autoimmune thyroid disorders.

Authors:  Ana Rodríguez-Muñoz; Marlen Vitales-Noyola; Ana Ramos-Levi; Ana Serrano-Somavilla; Roberto González-Amaro; Mónica Marazuela
Journal:  Endocrine       Date:  2015-06-23       Impact factor: 3.633

Review 7.  Regulatory T cells in autoimmune disease.

Authors:  Margarita Dominguez-Villar; David A Hafler
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

8.  Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.

Authors:  Shuang Yu; Chuanfang Liu; Lanhua Li; Tian Tian; Min Wang; Yu Hu; Cunzhong Yuan; Lei Zhang; Chunyan Ji; Daoxin Ma
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

Review 9.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 10.  Empowering Regulatory T Cells in Autoimmunity.

Authors:  Isaac R Kasper; Sokratis A Apostolidis; Amir Sharabi; George C Tsokos
Journal:  Trends Mol Med       Date:  2016-07-25       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.